Trial Profile
A Randomized Phase Ib/II Study of Preoperative GDC-0449 and Androgen Ablation Compared to Androgen Ablation Alone Followed by Radical Prostatectomy for Select Patients With Locally Advanced Adenocarcinoma of the Prostate.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary) ; Goserelin; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 20 Apr 2018 Status changed from active, no longer recruiting to discontinued.
- 08 Sep 2015 Planned primary completion date changed from 1 May 2020 to 1 Jan 2020 as reported by ClinicalTrials.gov
- 05 Sep 2012 Planned end date changed from 1 Jul 2012 to 1 May 2020 as reported by ClinicalTrials.gov.